Item request has been placed!

Item request cannot be made.

Processing Request

Search Results

Display Settings

Results per page: 10

Sort By: Relevance

Filter

Your Filters

Reset filters

Item request has been placed!

Item request cannot be made.

Processing Request

Academic Journal

Baricitinib: A 2018 Novel FDA-Approved Small Molecule Inhibiting Janus Kinases.

Authors : Mayence, Annie¹ (AUTHOR) ; Vanden Eynde, Jean Jacques² (AUTHOR)

Source: Pharmaceuticals (14248247). Mar2019, Vol. 12 Issue 1, p37-37. 1p.

Record details

Read Online Read More Add to Saved list

Academic Journal

Silence of MEG3 intensifies lipopolysaccharide-stimulated damage of human lung cells through modulating miR-4262.

Authors : Li, Xiaoliang¹ (AUTHOR); Zhang, Qianqian¹ (AUTHOR); Yang, Zhigang¹ (AUTHOR)

Source: Artificial Cells, Nanomedicine & Biotechnology. Dec2019, Vol. 47 Issue 1, p2369-2378. 10p.

Record details

Read Online Read More Add to Saved list

Academic Journal

Systematic review with meta‐analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease.

Authors : Choudhary, Daksh¹; Panaccione, Remo¹; Ma, Christopher^1,2

Source: Alimentary Pharmacology & Therapeutics. Jul2019, Vol. 50 Issue 1, p5-23. 19p. 11 Charts.

Record details

Read Online Read More Add to Saved list

Academic Journal

Noncanonical IFN Signaling, Steroids, and STATs: A Probable Role of V-ATPase.

Authors : Johnson, Howard M.¹; Noon-Song, Ezra¹; Ahmed, Chulbul M.¹

Source: Mediators of Inflammation. 5/28/2019, p1-11. 11p.

Record details

Read Online Read More Add to Saved list

Academic Journal

Serum amyloid A and Janus kinase 2 in a mouse model of diabetic kidney disease.

Authors : Dieter, Brad P.¹ ; Meek, Rick L.¹; Anderberg, Robert J.¹

Source: PLoS ONE. 2/14/2019, Vol. 14 Issue 2, p1-17. 17p.

Record details

Read Online Read More Add to Saved list

Academic Journal

Long‐term safety and tolerability of oral tofacitinib in patients with Crohn's disease: results from a phase 2, open‐label, 48‐week extension study.

Authors : Panés, Julián¹ (AUTHOR) ; D'Haens, Geert R.² (AUTHOR); Higgins, Peter D. R.³ (AUTHOR)

Source: Alimentary Pharmacology & Therapeutics. Feb2019, Vol. 49 Issue 3, p265-276. 12p. 2 Diagrams, 3 Charts, 5 Graphs.

Record details

Read Online Read More Add to Saved list

Academic Journal

Janus kinase inhibitors for inflammatory bowel disease.

Authors : Chaplin, Steve (AUTHOR)

Source: Prescriber. Jan2019, Vol. 30 Issue 1, p26-28. 3p.

Record details

Read Online Read More Add to Saved list

Academic Journal

Genetic and Real-World Clinical Data, Combined with Empirical Validation, Nominate Jak-Stat Signaling as a Target for Alzheimer's Disease Therapeutic Development.

Authors : Nevado-Holgado, Alejo J.^1,2 (AUTHOR) ; Ribe, Elena¹ (AUTHOR) ; Thei, Laura¹ (AUTHOR)

Source: Cells (2073-4409). May2019, Vol. 8 Issue 5, p425. 1p.

Record details

Read Online Read More Add to Saved list

Academic Journal

Persistent janus kinase‐signaling in chronic lymphocytic leukemia patients on ibrutinib: Results of a phase I trial.

Authors : Spaner, David E.^1,2,3,4,5 (AUTHOR) ; McCaw, Lindsay¹ (AUTHOR); Wang, Guizhei¹ (AUTHOR)

Source: Cancer Medicine. Apr2019, Vol. 8 Issue 4, p1540-1550. 11p.

Record details

Read Online Read More Add to Saved list

Academic Journal

CALR mutations in a cohort of JAK2 V617F negative patients with suspected myeloproliferative neoplasms.

Authors : Belcic Mikic, Tanja^1,2 ; Pajic, Tadej^1,3; Sever, Matjaz^1,2

Source: Scientific Reports. 12/27/2019, Vol. 9 Issue 1, p1-9. 9p.

Record details

Read Online Read More Add to Saved list

Search Results

Your Filters

Baricitinib: A 2018 Novel FDA-Approved Small Molecule Inhibiting Janus Kinases.

Silence of MEG3 intensifies lipopolysaccharide-stimulated damage of human lung cells through modulating miR-4262.

Systematic review with meta‐analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease.

Noncanonical IFN Signaling, Steroids, and STATs: A Probable Role of V-ATPase.

Serum amyloid A and Janus kinase 2 in a mouse model of diabetic kidney disease.

Long‐term safety and tolerability of oral tofacitinib in patients with Crohn's disease: results from a phase 2, open‐label, 48‐week extension study.

Janus kinase inhibitors for inflammatory bowel disease.

Genetic and Real-World Clinical Data, Combined with Empirical Validation, Nominate Jak-Stat Signaling as a Target for Alzheimer's Disease Therapeutic Development.

Persistent janus kinase‐signaling in chronic lymphocytic leukemia patients on ibrutinib: Results of a phase I trial.

CALR mutations in a cohort of JAK2 V617F negative patients with suspected myeloproliferative neoplasms.

Contact

Follow us